Sinohealth Holdings Full Year 2022 Earnings: Beats Expectations

Sinohealth Holdings (HKG:2361) Full Year 2022 Results

Key Financial Results

• Revenue: CN¥356.7m (up 10.0% from FY 2021).
• Net income: CN¥55.8m (down 29% from FY 2021).
• Profit margin: 16% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses.
• EPS: CN¥0.14 (down from CN¥0.34 in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sinohealth Holdings Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare Services industry in Asia.

Performance of the market in Hong Kong.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Sinohealth Holdings that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.